ReposiTrak Q1 Earnings Call Highlights

Nov 17, 2026
repositrak-q1-earnings-call-highlights

MarketBeat

5 min read

Key Points

  • Interested in ReposiTrak Inc.? Here are five stocks we like better.

  • Fiscal Q1 results declined year over year: Revenue fell about 3% to $5.8 million, while net income dropped to $1.5 million and diluted EPS to $0.08. The company cited delayed customer purchasing tied to the FDA traceability deadline extension and a focus on higher-margin recurring revenue.

  • ReposiTrak is expanding its investment in SPAR Group: Agreements are expected to give it approximately 49.99% of SPAR on an as-converted basis, along with preferred shares carrying an 8% cash or 10% in-kind annual dividend. The CEO expects the investment to contribute positively to near-term earnings.

  • Touchless Retail pilots are showing promise: Reported trials delivered sales gains of 17% and nearly 26%, and two pilots have advanced to rollouts. The service is already generating revenue, with a six-figure contribution expected in fiscal Q2.

ReposiTrak (NYSE:TRAK) reported lower revenue and profit for its fiscal first quarter of 2027, while executives said an expanded investment in SPAR Group and early results from a joint retail service could support future growth.

Revenue was $5.8 million, down approximately 3% from a year earlier but up about $200,000 from the preceding quarter. CFO John Merrill attributed the year-over-year decline primarily to an extension of the Food and Drug Administration’s traceability compliance deadline, which shifted the timing of some customer purchasing decisions, as well as the company’s emphasis on higher-margin recurring revenue.

→ MarketBeat Week in Review – 11/9 – 11/13

Net income fell to $1.5 million from $1.8 million, and diluted earnings per share declined to $0.08 from $0.09. Operating income was $1.7 million, compared with $1.9 million a year earlier, while operating margin narrowed to approximately 29% from 32%.

SPAR transaction expands economic interest

ReposiTrak has entered definitive agreements expected to give it approximately 49.99% of SPAR’s outstanding equity on an as-converted common stock basis, before any warrant exercise. Merrill emphasized that the figure represents the expected position under the agreements, not ReposiTrak’s ownership at the September 30 quarter-end.

→ Cerebras Q3 Results: How Much More Proof Does Wall Street Need?

Under the transaction, ReposiTrak will exchange its existing SPAR common shares and convert the $4 million principal of a SPAR note into a new class of preferred stock. The preferred shares carry a quarterly dividend calculated at an annual rate of 8% if paid in cash or 10% if paid in kind, or a proportional combination. ReposiTrak will also receive warrants and has agreed to provide SPAR with a new $1.5 million revolving credit facility.

Leave a comment